Showing 5201-5210 of 8624 results for "".
- Almirall and Evotec Form Dermatology Research Collaborationhttps://practicaldermatology.com/news/almirall-and-evotec-form-dermatology-research-collaboration/2457607/Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The two companies have for
- ASDS 2018 Survey: Patients Spend About $100 Per Month on Skin Care Productshttps://practicaldermatology.com/news/asds-2018-survey-patients-spend-about-100-per-month-on-skin-care-products/2457608/Almost 70 percent of consumers are considering a cosmetic treatment, and more than half would prefer to pay more up front to lower their annual skin care costs, according to the 2018 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Der
- Allergan Launches Spotlyte: Digital Hub Will Educate Consumers About Medical Aesthetic Treatmentshttps://practicaldermatology.com/news/allergan-launches-spotlyte/2457615/Allergan has launched Spotlyte, described as an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines.
- New Laser Handpiece Clears Multicolor Tattoos in Fewer Treatmentshttps://practicaldermatology.com/news/new-laser-handpiece-clears-multicolor-tattoos-in-fewer-treatments/2457613/A new titanium sapphire laser handpiece can clear green, blue, and purple tattoo pigments in fewer treatments, according to a new study in Lasers in Surgery and Medicine (LSM). Researchers led by American Soc
- Business News: Candela Acquires Ellipsehttps://practicaldermatology.com/news/business-news-candela-acquires-ellipse/2457616/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- Canfield Scientific Acquires Leading German Dermoscopy Company VISIOMED AGhttps://practicaldermatology.com/news/canfield-scientific-acquires-leading-german-dermoscopy-company-visiomed-ag/2457621/Canfield Scientific has acquired German company VISIOMED AG, which designs and manufactures dermoscopy systems. The resulting business has decades of experience in aesthetic documentation, 3D imaging, clinical photography, and reflected light microscopy leading to more choices and services for cu
- Carpe: New Antiperspirant Twice As Effective As "Extra Strength"https://practicaldermatology.com/news/carpe-new-antiperspirant-twice-as-effective-as-extra-strength/2457623/Carpe’s newly launched underarm antiperspirant has been demonstrated to reduce sweat twice as effectively as the US legal standard for extra strength antiperspirants, the company says. While federal regulation requires that an extra strength antiperspirant demonstrate at least a 30% r
- AbbVie to Present New Data at 27th EADV Congresshttps://practicaldermatology.com/news/abbvie-to-present-new-data-at-27th-eadv-congress/2457625/AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12-1
- JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharmahttps://practicaldermatology.com/news/jw-pharmaceutical-signs-global-out-licensing-agreement-for-atopic-dermatitis-drug-candidate-with-leo-pharma/2457626/JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to develop and commercialize JW1601 globally excluding Korea where JWP will maintain its exclusivity